Form 4: Bristol Myers Squibb Director Phyllis Yale's Ownership Update

Phyllis R. Yale, a Director at Bristol Myers Squibb, reported a transaction involving deferred share units.

Summary

• Phyllis R. Yale, a Director at Bristol Myers Squibb, filed a Form 4 statement detailing changes in her beneficial ownership.
• The filing indicates a transaction on June 30, 2026, involving 607.428 deferred share units.
• These deferred share units are convertible into shares of Bristol Myers Squibb common stock.
• Following this transaction, Ms. Yale beneficially owns 44,986.288 shares, including deferred compensation and reinvested dividends.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine disclosure of insider ownership changes rather than a significant strategic event.

Positives

• Director Phyllis R. Yale continues to hold a significant beneficial ownership in Bristol Myers Squibb, with 44,986.288 shares.
• The transaction involves deferred share units, suggesting a long-term commitment and alignment with company performance.

Future Outlook

The deferred share units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and reflect ongoing ownership adjustments by company leadership, which are closely watched by the market.

Stakeholder Impact

• Shareholders: The filing provides transparency into director ownership, which can influence investor confidence.
• Employees: Continued director investment may signal confidence in the company's future, potentially impacting employee morale.
• Creditors: Stable insider ownership can be viewed positively by creditors as an indicator of management commitment.

Next Steps

• Deferred share units will be converted into common stock upon settlement.
• Settlement will occur when the reporting person ceases to be a director or at a previously specified future date.

Key Dates

Keywords

Bristol Myers Squibb, Form 4, Beneficial Ownership, Director, Deferred Share Units, Insider Trading, SEC Filing